Clinical Trial Update: RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for RRx-001 in second-line treatment of advanced cholangiocarcinoma; study terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• RRx-001

Snippet

Sponsor: EpicentRx, Inc. | Conditions: Cholangiocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-04-24